Kiyatec Appoints Eric Perreault to President and Appoints Tessa DesRochers, PhD, Chief Scientific Officer to Vice President of Pre-Clinical Services

GREENVILLE, S.C.--(BUSINESS WIRE)-- Kiyatec, a leading biotechnology company specializing in 3D cell culture technologies, is pleased to announce the appointment of Eric Perreault to the position of President. Additionally, the company appoints Tessa DesRochers, PhD, Chief Scientific Officer to Vice President of Pre-Clinical Services. These strategic appointments demonstrate Kiyatec’s commitment to its mission of providing confidence to patients, oncologists, and pharmaceutical companies in their life-changing cancer therapy decisions through its functional precision assay, 3D Predict™, which accurately predicts patient-specific therapeutic response and nonresponse before treatment begins.

Eric Perreault has been an integral part of the Kiyatec team and has played a crucial role in shaping the company’s strategic direction. With his 28 years of diagnostic commercial experience and leadership acumen, Eric’s promotion to President marks a significant milestone in Kiyatec’s journey. As President, Eric will spearhead the company’s efforts to achieve commercial success by driving innovation, forging strategic partnerships, and expanding market reach.

“We are thrilled to announce Eric Perreault as the new President of Kiyatec,” said Matt Gevaert, PhD, Chief Executive Officer, and Co-Founder of Kiyatec. “Eric’s exceptional leadership, combined with his deep understanding of our technology and industry landscape, makes him the ideal candidate to take Kiyatec to new heights. We are confident that under Eric’s guidance, Kiyatec will continue to innovate and make a lasting impact on cancer treatment and drug discovery.”

As Vice President of Pre-Clinical Services, Tessa DesRochers, PhD brings a wealth of expertise in cellular biology and translational medicine. Dr. DesRochers’ appointment reflects Kiyatec’s commitment to scientific excellence and its dedication to advancing the frontiers of biomedical research. Her extensive background in pharmaceutical research, combined with her proven track record of leading successful pre-clinical programs, will be instrumental in driving Kiyatec’s scientific initiatives forward.

“We are delighted to name Dr. Tessa DesRochers as our VP of Pre-Clinical Services,” said Gevaert. “Her scientific expertise and leadership skills will be invaluable as we continue to deliver confidence in cancer therapy selection with KIYA-Predict™ and accelerate the development of lifesaving therapeutics. I am confident that, together, we will lead Kiyatec toward even greater success.”

As Kiyatec prepares for its next phase of growth and expansion, the company remains focused on advancing functional precision oncology with its 3D cell culture technologies. With Eric Perreault as President and Tessa DesRochers, PhD as Chief Scientific Officer and Vice President of Pre-Clinical Services, Kiyatec is poised to revolutionize cancer care and the way drugs are developed and tested, ultimately improving patient outcomes and transforming healthcare.

For more information about Kiyatec and its groundbreaking 3D Predict™ platform, please visit www.Kiyatec.com.

About Kiyatec:

Kiyatec is a functional precision oncology company that measures the response of an individual patient’s live cancer cells with its innovative 3D cell culture technology platform. They offer clinical testing for high-grade glioma and are developing tests for ovarian, breast, non-small cell lung, and rare tumors in their CLIA-certified laboratory. Kiyatec also works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors and aims to improve patient outcomes and revolutionize the field of precision medicine. For more information, visit www.Kiyatec.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230801566993/en/